Key statistics
On Monday, Vigil Neuroscience Inc (VIGL:NSQ) closed at 3.11, 25.91% above the 52 week low of 2.47 set on Jun 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.31 |
---|---|
High | 3.32 |
Low | 3.10 |
Bid | 2.82 |
Offer | 3.39 |
Previous close | 3.26 |
Average volume | 98.68k |
---|---|
Shares outstanding | 39.65m |
Free float | 36.23m |
P/E (TTM) | -- |
Market cap | 129.25m USD |
EPS (TTM) | -2.12 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 21:00 BST.
More ▼
- Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927
- Vigil Neuroscience to Present at Cantor Global Healthcare Conference
- Vigil Neuroscience to Present at Upcoming September Investor Conferences
- Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
- Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics
- Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)
- Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease
- Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference
- Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP
- Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
More ▼